Literature DB >> 22200823

Targeted therapies: can sunitinib use be expanded to other cancers?

Sarah Payton.   

Abstract

Entities:  

Year:  2011        PMID： 22200823     DOI： 10.1038/nrurol.2011.207

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  2 in total

1.  Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study.

Authors:  K Oechsle; F Honecker; T Cheng; F Mayer; P Czaykowski; E Winquist; L Wood; M Fenner; S Glaesener; J T Hartmann; K Chi; C Bokemeyer; C Kollmannsberger
Journal:  Ann Oncol       Date:  2011-03-17       Impact factor: 32.976

2.  Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.

Authors:  J Bellmunt; J L González-Larriba; C Prior; P Maroto; J Carles; D Castellano; B Mellado; E Gallardo; J L Perez-Gracia; G Aguilar; X Villanueva; J Albanell; A Calvo
Journal:  Ann Oncol       Date:  2011-03-21       Impact factor: 32.976
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.